TNFSF13B and systemic lupus erythematosus: Dual blockers may provide more potent and sustained inhibition of pathogenic B cell activity, inhibit the transformation of mature B cells into plasma cells, and promote the apoptosis of long-lived plasma cells by targeting BAFF and APRIL, thus providing the possibility to improve the disease activity in SLE more effectively22.